Allele-specific differences in transcriptome, miRNome, and mitochondrial function in two hypertrophic cardiomyopathy mouse models

Styliani Vakrou, Ryuya Fukunaga, D. Brian Foster, Lars Sorensen, Yamin Liu, Yufan Guan, Kirubel Woldemichael, Roberto Pineda-Reyes, Ting Liu, Jil C Tardiff, Leslie A. Leinwand, Carlo G. Tocchetti, Theodore P. Abraham, Brian O'Rourke, Miguel A. Aon, M. Roselle Abraham

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Hypertrophic cardiomyopathy (HCM) stems from mutations in sarcomeric proteins that elicit distinct biophysical sequelae, which in turn may yield radically different intracellular signaling and molecular pathologic profiles. These signaling events remain largely unaddressed by clinical trials that have selected patients based on clinical HCM diagnosis, irrespective of genotype. In this study, we determined how two mouse models of HCM differ, with respect to cellular/mitochondrial function and molecular biosignatures, at an early stage of disease. We show that hearts from young R92W-TnT and R403Q-αMyHC mutation-bearing mice differ in their transcriptome, miRNome, intracellular redox environment, mitochondrial antioxidant defense mechanisms, and susceptibility to mitochondrial permeability transition pore opening. Pathway analysis of mRNA-sequencing data and microRNA profiles indicate that R92W-TnT mutants exhibit a biosignature consistent with activation of profibrotic TGF-β signaling. Our results suggest that the oxidative environment and mitochondrial impairment in young R92W-TnT mice promote activation of TGF-β signaling that foreshadows a pernicious phenotype in young individuals. Of the two mutations, R92W-TnT is more likely to benefit from anti-TGF-β signaling effects conferred by angiotensin receptor blockers and may be responsive to mitochondrial antioxidant strategies in the early stage of disease. Molecular and functional profiling may therefore serve as aids to guide precision therapy for HCM.

Original languageEnglish (US)
JournalJCI insight
Volume3
Issue number6
DOIs
StatePublished - Mar 22 2018

Fingerprint

Hypertrophic Cardiomyopathy
Transcriptome
Alleles
Mutation
Antioxidants
Angiotensin Receptor Antagonists
MicroRNAs
Oxidation-Reduction
Genotype
Clinical Trials
Phenotype
Messenger RNA
Proteins
Therapeutics

Keywords

  • Cardiology
  • Cardiovascular disease
  • Cell Biology
  • Mitochondria
  • Transcription

Cite this

Allele-specific differences in transcriptome, miRNome, and mitochondrial function in two hypertrophic cardiomyopathy mouse models. / Vakrou, Styliani; Fukunaga, Ryuya; Foster, D. Brian; Sorensen, Lars; Liu, Yamin; Guan, Yufan; Woldemichael, Kirubel; Pineda-Reyes, Roberto; Liu, Ting; Tardiff, Jil C; Leinwand, Leslie A.; Tocchetti, Carlo G.; Abraham, Theodore P.; O'Rourke, Brian; Aon, Miguel A.; Abraham, M. Roselle.

In: JCI insight, Vol. 3, No. 6, 22.03.2018.

Research output: Contribution to journalArticle

Vakrou, S, Fukunaga, R, Foster, DB, Sorensen, L, Liu, Y, Guan, Y, Woldemichael, K, Pineda-Reyes, R, Liu, T, Tardiff, JC, Leinwand, LA, Tocchetti, CG, Abraham, TP, O'Rourke, B, Aon, MA & Abraham, MR 2018, 'Allele-specific differences in transcriptome, miRNome, and mitochondrial function in two hypertrophic cardiomyopathy mouse models', JCI insight, vol. 3, no. 6. https://doi.org/10.1172/jci.insight.94493
Vakrou, Styliani ; Fukunaga, Ryuya ; Foster, D. Brian ; Sorensen, Lars ; Liu, Yamin ; Guan, Yufan ; Woldemichael, Kirubel ; Pineda-Reyes, Roberto ; Liu, Ting ; Tardiff, Jil C ; Leinwand, Leslie A. ; Tocchetti, Carlo G. ; Abraham, Theodore P. ; O'Rourke, Brian ; Aon, Miguel A. ; Abraham, M. Roselle. / Allele-specific differences in transcriptome, miRNome, and mitochondrial function in two hypertrophic cardiomyopathy mouse models. In: JCI insight. 2018 ; Vol. 3, No. 6.
@article{8c998877723e4015ac7a75fa4b7ca31b,
title = "Allele-specific differences in transcriptome, miRNome, and mitochondrial function in two hypertrophic cardiomyopathy mouse models",
abstract = "Hypertrophic cardiomyopathy (HCM) stems from mutations in sarcomeric proteins that elicit distinct biophysical sequelae, which in turn may yield radically different intracellular signaling and molecular pathologic profiles. These signaling events remain largely unaddressed by clinical trials that have selected patients based on clinical HCM diagnosis, irrespective of genotype. In this study, we determined how two mouse models of HCM differ, with respect to cellular/mitochondrial function and molecular biosignatures, at an early stage of disease. We show that hearts from young R92W-TnT and R403Q-αMyHC mutation-bearing mice differ in their transcriptome, miRNome, intracellular redox environment, mitochondrial antioxidant defense mechanisms, and susceptibility to mitochondrial permeability transition pore opening. Pathway analysis of mRNA-sequencing data and microRNA profiles indicate that R92W-TnT mutants exhibit a biosignature consistent with activation of profibrotic TGF-β signaling. Our results suggest that the oxidative environment and mitochondrial impairment in young R92W-TnT mice promote activation of TGF-β signaling that foreshadows a pernicious phenotype in young individuals. Of the two mutations, R92W-TnT is more likely to benefit from anti-TGF-β signaling effects conferred by angiotensin receptor blockers and may be responsive to mitochondrial antioxidant strategies in the early stage of disease. Molecular and functional profiling may therefore serve as aids to guide precision therapy for HCM.",
keywords = "Cardiology, Cardiovascular disease, Cell Biology, Mitochondria, Transcription",
author = "Styliani Vakrou and Ryuya Fukunaga and Foster, {D. Brian} and Lars Sorensen and Yamin Liu and Yufan Guan and Kirubel Woldemichael and Roberto Pineda-Reyes and Ting Liu and Tardiff, {Jil C} and Leinwand, {Leslie A.} and Tocchetti, {Carlo G.} and Abraham, {Theodore P.} and Brian O'Rourke and Aon, {Miguel A.} and Abraham, {M. Roselle}",
year = "2018",
month = "3",
day = "22",
doi = "10.1172/jci.insight.94493",
language = "English (US)",
volume = "3",
journal = "JCI insight",
issn = "2379-3708",
publisher = "The American Society for Clinical Investigation",
number = "6",

}

TY - JOUR

T1 - Allele-specific differences in transcriptome, miRNome, and mitochondrial function in two hypertrophic cardiomyopathy mouse models

AU - Vakrou, Styliani

AU - Fukunaga, Ryuya

AU - Foster, D. Brian

AU - Sorensen, Lars

AU - Liu, Yamin

AU - Guan, Yufan

AU - Woldemichael, Kirubel

AU - Pineda-Reyes, Roberto

AU - Liu, Ting

AU - Tardiff, Jil C

AU - Leinwand, Leslie A.

AU - Tocchetti, Carlo G.

AU - Abraham, Theodore P.

AU - O'Rourke, Brian

AU - Aon, Miguel A.

AU - Abraham, M. Roselle

PY - 2018/3/22

Y1 - 2018/3/22

N2 - Hypertrophic cardiomyopathy (HCM) stems from mutations in sarcomeric proteins that elicit distinct biophysical sequelae, which in turn may yield radically different intracellular signaling and molecular pathologic profiles. These signaling events remain largely unaddressed by clinical trials that have selected patients based on clinical HCM diagnosis, irrespective of genotype. In this study, we determined how two mouse models of HCM differ, with respect to cellular/mitochondrial function and molecular biosignatures, at an early stage of disease. We show that hearts from young R92W-TnT and R403Q-αMyHC mutation-bearing mice differ in their transcriptome, miRNome, intracellular redox environment, mitochondrial antioxidant defense mechanisms, and susceptibility to mitochondrial permeability transition pore opening. Pathway analysis of mRNA-sequencing data and microRNA profiles indicate that R92W-TnT mutants exhibit a biosignature consistent with activation of profibrotic TGF-β signaling. Our results suggest that the oxidative environment and mitochondrial impairment in young R92W-TnT mice promote activation of TGF-β signaling that foreshadows a pernicious phenotype in young individuals. Of the two mutations, R92W-TnT is more likely to benefit from anti-TGF-β signaling effects conferred by angiotensin receptor blockers and may be responsive to mitochondrial antioxidant strategies in the early stage of disease. Molecular and functional profiling may therefore serve as aids to guide precision therapy for HCM.

AB - Hypertrophic cardiomyopathy (HCM) stems from mutations in sarcomeric proteins that elicit distinct biophysical sequelae, which in turn may yield radically different intracellular signaling and molecular pathologic profiles. These signaling events remain largely unaddressed by clinical trials that have selected patients based on clinical HCM diagnosis, irrespective of genotype. In this study, we determined how two mouse models of HCM differ, with respect to cellular/mitochondrial function and molecular biosignatures, at an early stage of disease. We show that hearts from young R92W-TnT and R403Q-αMyHC mutation-bearing mice differ in their transcriptome, miRNome, intracellular redox environment, mitochondrial antioxidant defense mechanisms, and susceptibility to mitochondrial permeability transition pore opening. Pathway analysis of mRNA-sequencing data and microRNA profiles indicate that R92W-TnT mutants exhibit a biosignature consistent with activation of profibrotic TGF-β signaling. Our results suggest that the oxidative environment and mitochondrial impairment in young R92W-TnT mice promote activation of TGF-β signaling that foreshadows a pernicious phenotype in young individuals. Of the two mutations, R92W-TnT is more likely to benefit from anti-TGF-β signaling effects conferred by angiotensin receptor blockers and may be responsive to mitochondrial antioxidant strategies in the early stage of disease. Molecular and functional profiling may therefore serve as aids to guide precision therapy for HCM.

KW - Cardiology

KW - Cardiovascular disease

KW - Cell Biology

KW - Mitochondria

KW - Transcription

UR - http://www.scopus.com/inward/record.url?scp=85050349295&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050349295&partnerID=8YFLogxK

U2 - 10.1172/jci.insight.94493

DO - 10.1172/jci.insight.94493

M3 - Article

VL - 3

JO - JCI insight

JF - JCI insight

SN - 2379-3708

IS - 6

ER -